Posted by Michael Wonder on 29 Sep 2024
AbbVie submits biologics license application to the FDA for telisotuzumab vedotin in previously treated non-small cell lung cancer
27 September 2024 - Biologics license application submission for accelerated approval is supported by data from the Phase 2 LUMINOSITY trial (M14-239).
AbbVie today announced submission of a biologics license application to the US FDA for accelerated approval of telisotuzumab vedotin in adult patients with previously treated, locally advanced or metastatic epidermal growth factor receptor wild type, non-squamous non-small cell lung cancer with c-Met protein overexpression.
